Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases.

Paulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R.

Andrology. 2013 Jan;1(1):120-8. doi: 10.1111/j.2047-2927.2012.00007.x. Epub 2012 Sep 7.

3.

Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases.

Paulis G, D'Ascenzo R, Nupieri P, De Giorgio G, Orsolini G, Brancato T, Alvaro R.

Int J Androl. 2012 Aug;35(4):521-7. doi: 10.1111/j.1365-2605.2011.01219.x. Epub 2011 Sep 27.

4.

Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study.

Paulis G, Cavallini G, Brancato T, Alvaro R.

Inflamm Allergy Drug Targets. 2013 Feb;12(1):61-7.

PMID:
23004005
5.
6.
7.
8.

Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, Gennaro R.

Res Rep Urol. 2015 Dec 31;8:1-10. doi: 10.2147/RRU.S97194. eCollection 2016.

9.

[Transdermal iontophoresis with dexamethasone and verapamil for Peyronie's disease].

Cabello Benavente R, Moncada Iribarren I, de Palacio España A, Hernández Villaverde A, Monzó JI, Hernández Fernández C.

Actas Urol Esp. 2005 Nov-Dec;29(10):955-60. Spanish.

PMID:
16447593
10.

Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study.

Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M.

J Sex Med. 2007 Mar;4(2):477-84.

PMID:
17367443
11.

Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.

Pavone C, Napoli G, Caruana G, Alonge V, Usala M, Abbadessa D.

BJU Int. 2012 Jul;110(1):117-21. doi: 10.1111/j.1464-410X.2011.10733.x. Epub 2011 Dec 16.

12.

Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.

Gennaro R, Barletta D, Paulis G.

Int Urol Nephrol. 2015 Oct;47(10):1595-602. doi: 10.1007/s11255-015-1074-1. Epub 2015 Aug 11.

PMID:
26257044
13.

Transdermal iontophoresis with verapamil and dexamethasone in the acute phase of peyronie's disease. Our experience.

Garrido Abad P, Coloma A, Herranz LM, Jiménez M, Suárez C, Prieto MD, Formoso T, Fernández Arjona M.

Arch Esp Urol. 2012 Oct;65(8):745-51. English, Spanish.

PMID:
23117682
14.

Iontophoresis for treatment of Peyronie's disease.

Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H.

J Urol. 2000 Jan;163(1):95-9.

PMID:
10604323
15.
16.

[Iontophoresis in the conservative treatment of Peyronie's disease: preliminary experience].

Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C.

Arch Ital Urol Androl. 1997 Dec;69(5):323-7. Italian.

PMID:
9477619
17.

Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study.

Favilla V, Russo GI, Privitera S, Castelli T, Madonia M, La Vignera S, Condorelli R, Calogero AE, Farina FP, Cimino S, Morgia G.

Andrologia. 2014 Oct;46(8):936-42. doi: 10.1111/and.12178. Epub 2013 Oct 11.

PMID:
24124921
18.

Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study.

Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S.

Int Urol Nephrol. 2009;41(3):467-71. doi: 10.1007/s11255-009-9522-4. Epub 2009 Feb 6.

PMID:
19199072
19.

Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.

Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, Scattoni V, Rigatti P, Pizzini G.

J Androl. 2000 Jan-Feb;21(1):85-90.

20.

Intralesional verapamil prevents the progression of Peyronie's disease.

Bennett NE, Guhring P, Mulhall JP.

Urology. 2007 Jun;69(6):1181-4.

PMID:
17572211

Supplemental Content

Support Center